Live Global Coronavirus News: White House Says It’s Bracing for an Autumn Wave

“Each day, each hour of class counts,” Mr. Blanquer told France Inter radio, adding that confinement had been a “global education catastrophe” for students and that those who had dropped behind during the lockdown would receive special support.France started reopening schools after lifting a nationwide lockdown on May 11, but progress was slow and depended on the age of the children and the location of their school. In many places, schools had remained closed; those that had reopened often did so on reduced schedules.Before Monday, only 1.8 million elementary-school children had gone back to school, out of 6.7 million in total, according to the Education Ministry. For middle schools, that figure was only 600,000, out of 3.3 million, according to the ministry.The pandemic has killed over 29,500 people in France but the number of hospitalizations has continued to fall, and clusters of cases that have emerged since the lockdown was lifted have remained under control.An easier-to-administer treatment moves to human trials.Gilead Sciences, an American biopharmaceutical company, will soon start trials of an inhalable version of remdesivir, an antiviral drug that has shown some preliminary promise as a virus treatment, the company said in a statement on Monday.Currently, remdesivir is given intravenously, which restricts its use to hospitals. Gilead’s inhalable version of the treatment would be administered through a nebulizer, a device often used to treat asthma patients, that sends a mist of therapeutic liquid into the airway. Gilead scientists hope that a more convenient treatment could be used by patients at various stages of infection.Nebulizers are more commonly available than IV equipment, said Angela Rasmussen, a virologist at Columbia University. “Pretty much every outpatient urgent care clinic has them.” She said that the device could potentially be used to immediately treat people who have tested positive but lack symptoms.

Recent Articles

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here

Stay on op - Ge the daily news in your inbox